ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.Reviews in medical virology · 2026Pooled it
- Convalescent plasma for persistent symptomatic COVID-19 infection in immune-suppressed patients - a case series.Infectious medicine · 2026Article
- Autoantibodies in COVID-19 convalescent plasma donors.Vox sanguinis · 2026Article
- Describing a Persistent SARS-CoV-2 Infection Outcomes and Mutations Associated With B-Cell Deficiency: A Case Report.Case reports in infectious diseases · 2026Article
- COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.Expert review of anti-infective therapy · 2026Review
- Review
- Stable SARS-CoV-2 antibody levels and functionality in serum and COVID-19 convalescent plasma after long-term storage.Vox sanguinis · 2025Article
- A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.The Journal of infectious diseases · 2025Article
- SARS-CoV-2 IgG antibodies in COVID-19 convalescent plasma and conventional plasma units.Transfusion · 2025Article
- Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection.Infectious disease reports · 2025Article
- Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19.Current research in microbial sciences · 2025Article
- Convalescent Plasma for Immunocompromised Patients.Current topics in microbiology and immunology · 2025Review
- COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis.Frontiers in medicine · 2025Article
- Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2024Review
- Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report.Frontiers in immunology · 2024Article
- The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review.Life (Basel, Switzerland) · 2023Article
- Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients.Pathogens (Basel, Switzerland) · 2023Review
- Misinterpretation of Clinical Research Findings and COVID-19 Mortality.Annals of internal medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.